Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus
erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it …

Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …

Objective AURORA 2 evaluated the long‐term safety, tolerability, and efficacy of voclosporin
compared to placebo in patients with lupus nephritis (LN) receiving an additional two years …

Abstract Purpose of Review Discuss the prognostic significance of kidney flares in patients
with lupus nephritis, associated risk factors, and possible preventative strategies. Recent …

Objective To assess mortality rates (MRs), standardized mortality ratios, and causes of death
in systemic lupus erythematosus (SLE) in a population-based study. Methods We analyzed …

Background Belimumab was recently approved for treatment of lupus glomerulonephritis
(LN). Aim To evaluate renal response and its predictors in LN patients receiving belimumab …

Although the prognosis of lupus nephritis (LN) has improved over the last few decades, 5–
20% of patients still progress to kidney failure. Hence, there is an unmet need to improve the …

In anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), hematuria and
proteinuria are biomarkers reflecting kidney involvement at diagnosis. Yet, the prognostic …

In 2020 many contributions have been produced on SLE. Our critical digest of the recent
literature will be focused on genetic factors that contribute to the development of the disease …

Objectives Whether immunosuppressive therapy may be safely withdrawn in lupus nephritis
(LN) is still unclear. We assessed rate and predictors of flare after IS withdrawal in patients …